Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005264 | 0.90 | GFER (0.55) | ADORA1GFERPOLBSLC16A3SLC16A1 | |
| SCHEMBL5008839 | 0.90 | ADORA1 (0.47) | ADORA1MAPTTP53 | |
| SCHEMBL5008399 | 0.88 | ADORA1 (0.55) | ADORA1GFERPOLBSLC16A3SLC16A1 | |
| SCHEMBL5008583 | 0.87 | ADORA1 (0.62) | ADORA1GFERPOLBSLC16A3SLC16A1 | |
| SCHEMBL5007784 | 0.87 | ADORA1 (0.51) | ADORA1POLBMAPT | |
| SCHEMBL5008553 | 0.86 | ADORA1 (0.59) | ADORA1GFERMAPTADORA3TP53 | |
| SCHEMBL5008457 | 0.85 | ADORA1 (0.47) | ADORA1POLBMAPTTP53 | |
| SCHEMBL5008431 | 0.83 | ADORA1 (0.62) | ADORA1AKR1C3AKR1C2GFERMAPT | |
| SCHEMBL27637159 | 0.83 | POLB (0.52) | ADORA1AKR1C3AKR1C2GFERPOLB | |
| SCHEMBL5011987 | 0.82 | ADORA1 (0.66) | ADORA1GFERPOLBMAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885AKR1C3 1060/4885AKR1C2 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.